# Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

> **NIH NIH U19** · BOSTON CHILDREN'S HOSPITAL · 2024 · $199,833

## Abstract

PROJECT SUMMARY: IDEAL Administrative Core
Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes
that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious
disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow
complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3)
research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the
study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed
studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute
streamlined processes which facilitate productive interactions among investigators from each IDEAL Project
and Core. We will achieve this goal by pursuing the following Specific Aims (SAs):
SA1. Provide infrastructure for administrative leadership aimed at building an interactive and
collaborative working team resulting in maximal project synergy.
SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads
by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as
seminars/symposia focused on the IDEAL project.
SA3. Manage and optimize communication within our IDEAL team and between our team, the
other NIH supported IDEAL teams and the IDEAL Steering Committee.
SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by
implementing recommendations of the Conflicts Resolution Group (CRG).
SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress
reports sent to the NIH.
SA6. Protect intellectual property rights of our investigators and execute material transfer
agreements.
SA7. Implement the data management/sharing plan among investigators within and outside of our
IDEAL team.
Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to
project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.

## Key facts

- **NIH application ID:** 10796876
- **Project number:** 5U19AI168643-03
- **Recipient organization:** BOSTON CHILDREN'S HOSPITAL
- **Principal Investigator:** OFER LEVY
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $199,833
- **Award type:** 5
- **Project period:** 2022-03-10 → 2027-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10796876

## Citation

> US National Institutes of Health, RePORTER application 10796876, Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma (5U19AI168643-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10796876. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*